BLAINJECTIONINJECTABLE
Approved
Aug 2011
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
58
Data completeness
6/8 — Strong
ADCETRIS (brentuximab vedotin) by Pfizer is cd30 is a member of the tumor necrosis factor receptor family and is expressed on the surface of salcl cells and on hodgkin reed-sternberg (hrs) cells in chl. Approved for hodgkin lymphoma, anaplastic large cell lymphoma. First approved in 2011.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ADCETRIS (brentuximab vedotin) is an antibody-drug conjugate (ADC) that targets CD30-expressing hematologic malignancies and is being investigated across solid tumors and autoimmune diseases. It binds to CD30 on tumor cells, internalizes, and releases MMAE, a microtubule-disrupting agent that triggers apoptosis. The drug has expanded from approved indications in Hodgkin lymphoma and anaplastic large cell lymphoma to active clinical exploration in multiple B-cell and T-cell malignancies, solid tumors, and systemic autoimmune conditions.
$3MPart D
PeakADCETRIS remains in peak commercial phase with modest Part D spending, indicating mature market positioning and stable brand team structure at Pfizer.
Mechanism of Action
CD30 is a member of the tumor necrosis factor receptor family and is expressed on the surface of sALCL cells and on Hodgkin Reed-Sternberg (HRS) cells in cHL. CD30 is variably expressed in other T-cell lymphomas. Expression of CD30 on healthy tissue and cells is limited. In vitro data suggest that…
Indications (2)
Worked on ADCETRIS at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.